Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide cardiovascular outcomes study in type 2 diabetes at high cardiovascular risk
2017-002954-35Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Time to first Major Adverse Cardiovascular Event (MACE). Started Mar 2018; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-002954-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002954-35.